

SOMETHING BETTER THAN HOPE

CIRM Business Development Update

ICOC Meeting

June 18, 2021

Shyam Patel, Ph.D.
Director, Business Development

CIRM
CALIFORNIA / STEM CELL AGENCY

CIRM-Funded Projects Attract Industry Support

CIRM's funding model accelerates and de-risks therapeutic development programs until they obtain early data to attract industry partnerships.

Highlighted Measures of Industry Partnering by CIRM-funded projects:

- Over **50%** of CIRM-funded Clinical Projects are partnered with Industry.
- **6** CIRM-funded companies have gone public & **4** were acquired.
- CIRM-funded projects have attracted at least **\$18.2B** in industry investments.
- CIRM funding of academic projects has contributed to the spin out of **46** companies.
- Industry partnering of CIRM-funded projects has potential to generate returns for the state.

2021: Highlighted Industry Partnering Events

 celularity	Allogeneic Cell Immunotherapies for COVID & Cancer	SPAC Acquisition - \$372M in proceeds
	Non-toxic conditioning and cell engineering for HSC transplants	SPAC Acquisition - \$200M in proceeds
 GRAPHITE BIO	CRISPR Therapies for Blood Disorders	\$150M Series B Venture Financing
	Cells Therapy for Spinal Cord Injury	\$57M At-the-Market Offering & Sale of Holdings
	Allogeneic Cell Immunotherapies for Cancer	\$52M Series A Financing



INDUSTRY
ALLIANCE
PROGRAM


CIRM's Industry Alliance Program (IAP): A unique opportunity for the industry to partner with CIRM in accelerating clinical and preclinical stem cell, gene and regenerative medicine therapy programs to market.



PANACEA VENTURE
HEALTHCARE



BlueRock
Therapeutics



CIRM Partner Day Hosted by Biocom (March 2021)

Public Plenary Session – March 9

- CIRM Presentation on Funding Model
- 2 Panels Sessions
 - Partnered CIRM Grantees: Jasper Therapeutics, Poseida Therapeutics, Viacyte, Rocket Pharma
 - Emerging Advanced Therapies: Dr. Diana Farmer (UCD), Dr. Anthony Oro (Stanford), Dr. Jack Reidling (Dr. Thompson Lab, UCI)
- 129 Attendees representing Academia, Biotech, Biopharma, Investors
- Event recorded and hosted on CIRM Youtube channel



1:1 Meetings between CIRM Grantees & Biocom Industry Partners

- 30 CIRM Grantees
- 21 Biocom Industry Partners

1:1 Meetings between Potential Applicants & CIRM

- 17 Requests



CIRM Manufacturing in California Workshop – April 14, 2021

CIRM convened an all-day virtual workshop of over 50 leaders in cell and gene therapy manufacturing to help it define collaborative solutions to the manufacturing and workforce needs in California.

- Leaders represented:
 - Academic GMP Manufacturing Facilities
 - Community Colleges
 - CDMOs
 - Supply Chain Partners
 - CIRM Grantees & IAP Partners
 - NCATS
 - Consulting Groups



CIRM Manufacturing in California Workshop – Three Themes

Session 1 - Incorporating Practical QbD Principles in Cell and Gene Therapy Manufacturing Development

Session 2 - Operationalizing a Public-Private CA Manufacturing Network

Session 3 - Training a Diverse Manufacturing Workforce



CIRM Manufacturing in California Workshop – Key Takeaways

- Empower academic innovators to adopt manufacturing best practices
- Enable competency hubs and GMP manufacturing centers of excellence
- Build a public-private manufacturing network that supports projects from early translation to commercialization
- Leverage CIRM education programs and the public-private network to build faster on-ramps for manufacturing career pathways

